Kraj: Izrael
Język: hebrajski
Źródło: Ministry of Health
BELATACEPT 25 MG/ML
BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED
L04AA28
POWDER FOR CONCENTRATE FOR INFUSION
I.V
BRISTOL-MYERS SQUIBB S.R.L, ITALY
BELATACEPT
Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen
2012-08-01